Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the ...

RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

Influenza vaccine recommendations made for upcoming season; patient dies following Elevidys infusion; Chikungunya vaccine now available and recommended ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...

As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...